Anti-Fas/APO-1 antibody-mediated apoptosis of cultured human glioma cells. Induction and modulation of sensitivity by cytokines.
Open accessThe DOI matches its Crossref record; 57 of the 57 references it cites were found in a registry or an index.
Abstract
Fas/APO-1 is a transmembrane protein of the nerve growth factor/TNF alpha receptor family which signals apoptotic cell death in susceptible target cells. We have investigated the susceptibility of seven human malignant glioma cell lines to Fas/APO-1-dependent apoptosis. Sensitivity to Fas/APO-1 antibody-mediated cell killing correlated with cell surface expression of Fas/APO-1. Expression of Fas/APO-1 as well as Fas/APO-1-dependent cytotoxicity were augmented by preexposure of human malignant glioma cells to IFN gamma and TNF alpha. Further, pretreatment with TGF beta 2, IL1 and IL8 enhanced Fas/APO-1 antibody-induced glioma cell apoptosis whereas other cytokines including TNF beta, IL6, macrophage colony-stimulating factor, IL10 and IL13 had no such effect. None of the human malignant glioma cell lines was susceptible to TNF alpha-induced cytotoxicity. Fas/APO-1 antibody-sensitive glioma cell lines (n = 5), but not Fas/APO-1 antibody-resistant glioma cell lines (n = 2), became sensitive to TNF alpha when co-treated with inhibitors of RNA and protein synthesis. Resistance of human glioma cells to Fas/APO-1 antibody-mediated apoptosis was mainly related to low level expression of Fas/APO-1 and appeared not to be linked to overexpression of the anti-apoptotic protooncogene, bcl-2. Given the resistance of human malignant glioma to surgery, irradiation, chemotherapy and immunotherapy, we propose that Fas/APO-1 may be a promising target for a novel locoregionary approach to human malignant glioma. This strategy gains support from the demonstration of Fas/APO-1 expression in ex vivo human malignant glioma specimens and from the absence of Fas/APO-1 in normal human brain parenchyma.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Apoptosis: A Basic Biological Phenomenon with Wideranging Implications in Tissue Kinetics
Kerr, J. F. R., Wyllie, A. H., & Currie, A. R. (1972) · British Journal of Cancer · doi:10.1038/bjc.1972.33 · Cited by 15,725
Identification of programmed cell death in situ via specific labeling of nuclear DNA fragmentation.
Gavrieli, Y., Sherman, Y., & Ben-Sasson, S. A. (1992) · The Journal of cell biology · doi:10.1083/jcb.119.3.493 · Cited by 9,444
Bcl-2 functions in an antioxidant pathway to prevent apoptosis
Hockenbery, D. M., Oltvai, Z. N., Yin, X.-M., Milliman, C. L., & Korsmeyer, S. J. (1993) · Cell · doi:10.1016/0092-8674(93)80066-n · Cited by 3,419
Lymphoproliferation disorder in mice explained by defects in Fas antigen that mediates apoptosis
Watanabe-Fukunaga, R., Brannan, C. I., Copeland, N. G., Jenkins, N. A., & Nagata, S. (1992) · Nature · doi:10.1038/356314a0 · Cited by 2,885
The polypeptide encoded by the cDNA for human cell surface antigen Fas can mediate apoptosis
Itoh, N., Yonehara, S., Ishii, A., Yonehara, M., Mizushima, S.-I., Sameshima, M., Hase, A., Seto, Y., & Nagata, S. (1991) · Cell · doi:10.1016/0092-8674(91)90614-5 · Cited by 2,737
Suda, T., Takahashi, T., Golstein, P., & Nagata, S. (1993) · Cell · doi:10.1016/0092-8674(93)90326-l · Cited by 2,489
Bcl-2 and the regulation of programmed cell death
Reed, J. (1994) · The Journal of cell biology · doi:10.1083/jcb.124.1.1 · Cited by 2,305
The Pathophysiology Of Tumor Necrosis Factors
VASSALLI, P. (1992) · Annual Review of Immunology · doi:10.1146/annurev.immunol.10.1.411 · Cited by 1,920
Lethal effect of the anti-Fas antibody in mice
Ogasawara, J., Watanabe-Fukunaga, R., Adachi, M., Matsuzawa, A., Kasugai, T., Kitamura, Y., Itoh, N., Suda, T., & Nagata, S. (1993) · Nature · doi:10.1038/364806a0 · Cited by 1,881
Monoclonal Antibody-Mediated Tumor Regression by Induction of Apoptosis
Trauth, B. C., Klas, C., Peters, A. M. J., Matzku, S., Möller, P., Falk, W., Debatin, K.-M., & Krammer, P. H. (1989) · Science · doi:10.1126/science.2787530 · Cited by 1,716
Self-citation
Cited by
Malignant astrocytic glioma: genetics, biology, and paths to treatment
Furnari, F. B., Fenton, T., Bachoo, R. M., Mukasa, A., Stommel, J. M., Stegh, A., Hahn, W. C., Ligon, K. L., Louis, D. N., Brennan, C., et al. (2007) · Genes & Development · doi:10.1101/gad.1596707 · Cited by 2,316
“First, various human glioma cell lines and primary glioma-derived cell cultures are sensitive to death ligand-mediated apoptosis in vitro and in xenograft model systems in vivo (Weller et al. 1994; Roth et al. 1997; Shinoura et al. 1998; Nagane et al. 2000; Maleniak et al. 2001; Rohn et al. 2001).”
BackgroundThe Fas counterattack: Fas-mediated T cell killing by colon cancer cells expressing Fas ligand.
O'Connell, J., O'Sullivan, G. C., Collins, J. K., & Shanahan, F. (1996) · The Journal of experimental medicine · doi:10.1084/jem.184.3.1075 · Cited by 878
Fas ligand expression by astrocytoma in vivo: maintaining immune privilege in the brain?
Saas, P., Walker, P. R., Hahne, M., Quiquerez, A. L., Schnuriger, V, Perrin, G., French, L., Van Meir, E. G., de Tribolet, N., Tschopp, J., et al. (1997) · Journal of Clinical Investigation · doi:10.1172/jci119273 · Cited by 398
Multiple Sclerosis: Fas Signaling in Oligodendrocyte Cell Death
D'Souza, S. D., Bonetti, B., Balasingam, V., Cashman, N. R., Barker, P. A., Troutt, A. B., Raine, C. S., & Antel, J. P. (1996) · The Journal of Experimental Medicine · doi:10.1084/jem.184.6.2361 · Cited by 354
A Functional Role of HLA-G Expression in Human Gliomas: An Alternative Strategy of Immune Escape
Wiendl, H., Mitsdoerffer, M., Hofmeister, V., Wischhusen, J., Bornemann, A., Meyermann, R., Weiss, E. H., Melms, A., & Weller, M. (2002) · The Journal of Immunology · doi:10.4049/jimmunol.168.9.4772 · Cited by 325
Self-citationImmune defects observed in patients with primary malignant brain tumors
Dix, A. R., Brooks, W. H., Roszman, T. L., & Morford, L. A. (1999) · Journal of Neuroimmunology · doi:10.1016/s0165-5728(99)00203-9 · Cited by 323
Schulz, J. B., Weller, M., & Klockgether, T. (1996) · The Journal of Neuroscience · doi:10.1523/jneurosci.16-15-04696.1996 · Cited by 321
Self-citationHermisson, M., Klumpp, A., Wick, W., Wischhusen, J., Nagel, G., Roos, W., Kaina, B., & Weller, M. (2006) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2005.03583.x · Cited by 311
Self-citationYes and PI3K Bind CD95 to Signal Invasion of Glioblastoma
Kleber, S., Sancho-Martinez, I., Wiestler, B., Beisel, A., Gieffers, C., Hill, O., Thiemann, M., Mueller, W., Sykora, J., Kuhn, A., et al. (2008) · Cancer Cell · doi:10.1016/j.ccr.2008.02.003 · Cited by 309
Krakstad, C., & Chekenya, M. (2010) · Molecular Cancer · doi:10.1186/1476-4598-9-135 · Cited by 301
Involvement of the CD95 (APO-1/Fas) receptor/ligand system in multiple sclerosis brain.
Dowling, P., Shang, G., Raval, S., Menonna, J., Cook, S., & Husar, W. (1996) · The Journal of experimental medicine · doi:10.1084/jem.184.4.1513 · Cited by 273
Fas ligand/Fas system in the brain: regulator of immune and apoptotic responses
Choi, C., & Benveniste, E. N. (2004) · Brain Research Reviews · doi:10.1016/j.brainresrev.2003.08.007 · Cited by 270
Geng, Y.-J., Henderson, L. E., Levesque, E. B., Muszynski, M., & Libby, P. (1997) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/01.atv.17.10.2200 · Cited by 267
Protein-based therapeutic approaches targeting death receptors
French, L. E., & Tschopp, J. (2003) · Cell Death & Differentiation · doi:10.1038/sj.cdd.4401185 · Cited by 102
Sensitivity of Ewing's sarcoma to TRAIL-induced apoptosis
Kontny, H. U., Hämmerle, K., Klein, R., Shayan, P., Mackall, C. L., & Niemeyer, C. M. (2001) · Cell Death & Differentiation · doi:10.1038/sj.cdd.4400836 · Cited by 90
Wisniewski, P., Ellert-Miklaszewska, A., Kwiatkowska, A., & Kaminska, B. (2010) · Cellular Signalling · doi:10.1016/j.cellsig.2009.09.016 · Cited by 46
Metadata
- Authors
- Weller, M., Frei, K., Groscurth, P., Krammer, P. H., Yonekawa, Y., & Fontana, A.
- Venue
- Journal of Clinical Investigation
- Published
- 1994-09-01
- Volume
- 94
- Issue
- 3
- Pages
- 954-964
- ISSN
- 0021-9738 (ISSN-L)
- OpenAlex
- W2166487006
- Cited by
- 345
- References
- 57
- FWCI
- 7.48
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.